NCT05949203 (OR-PrEP@Home) is a clinical trial of Cabotegravir Injection in HIV/AIDS, sponsored by Oregon Health and Science University.

Who is sponsoring NCT05949203?

NCT05949203 is sponsored by Oregon Health and Science University.

What drugs are being tested in NCT05949203?

Interventions in NCT05949203: Cabotegravir Injection.

Is NCT05949203 still recruiting?

NCT05949203 is currently status unknown. Last updated 6 December 2023.

Last reviewed 2023-12-06 · How we verify

NCT05949203: OR-PrEP@Home

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oregon PrEP at Home Study

Status unknown Last updated 6 December 2023

What this trial tests

trial testing Cabotegravir Injection in HIV/AIDS in 125 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	Oregon Health and Science University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	125
Start date	1 December 2023
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across United States

Drugs / interventions tested

Cabotegravir Injection — full drug profile →

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

Oregon Health and Science University

Who can join

18 and older, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This demonstration study will evaluate the real-world implementation of long-acting cabotegravir (CAB-LA) for HIV pre-exposure prevention (PrEP) through a partnership between the OHSU Tele-PrEP Program (TPP) and the OHSU Home Infusion Pharmacy (HIP). The study will perform a formative evaluation of the TPP/HIP partnership to determine its merit and worth, with revisions made as needed to improve the program, which is reflective of a real-world program rollout. The study is observational, and there is no comparison group. The primary objective is to evaluate adherence to CAB-LA by both urban and rural participants using the TPP/HIP partnership. The goals of the study are improve the TPP/HIP program itself with attention to reducing geographic disparities, and to disseminate best practices and lessons learned to the broader HIV prevention community.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Oregon Health and Science University trials

Trials by the same sponsor.

NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05949203 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
Last refreshed: 6 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05949203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing